{'fraction_non_alphanumeric': 0.008902077151335312, 'fraction_numerical': 0.004451038575667656, 'mean_word_length': 6.180851063829787, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.

Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis. This study describes a girl aged 2 years 9 months with end-stage renal disease resulting from crescent glomerulonephritis and severe interstitial nephritis who developed leukocytosis with a predominance of lymphocytes in the dialysate effluent, and in whom the effluent cell count normalized 1 week after discontinuation of amlodipine besylate therapy. Rechallenge confirmed that amlodipine was the offending agent causing effluent leukocytosis.